Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth $20 Billion, While Mast Therapeutics Is 'Worthless'

By: via Benzinga
Martin Shkreli thinks Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) is wildly undervalued. Shkreli, who appeared on ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.